… BRAF V600E andTERTpromoter mutations can coexist in papillary thyroid cancer (PTC).
This genetic duet was indicated to be involved in the aggressiveness of PTC, but its prognostic …

… targeted monotherapy for BRAF V600E -positive anaplastic thyroid carcinomas (ATC) is not
established. We report 2 cases of BRAF V600E -positive ATC treated with a BRAF inhibitor. …

… In thyroid cancer, occurrence of the BRAF V600E mutation only occurs in its papillary and
anaplastic subtypes, with a frequency of approximately 45% (range, 27–87%) in PTC patients.8…

… that BRAF V600E mutation occurs more frequently in aggressive PTC. The purpose of this
study was to evaluate BRAF V600E … age, large tumors and BRAF V600E mutation should be …

… an association between BRAF V600E and older … BRAF V600E might play an important role
in the effect of patient age on PTC-specific mortality, and that, in the absence of BRAF V600E, …

… of the BRAF V600E mutation in papillary thyroid carcinoma (PTC) … BRAF V600E mutation
status was analyzed in 206 thyroid … the BRAF V600E mutation with clinicopathological features. …

… association of the BRAF V600E mutation with prognostic factors and poor clinical outcome
in papillary thyroid cancer. This meta-analysis demonstrates that the BRAF V600E mutation is …

… Most of our knowledge on the status of BRAF V600E in thyroid cancer is based on Sanger
sequencing, which has low analytical sensitivity and does not provide quantitative information …

… for BRAF V600E mutation in thyroid nodule, if positive, would seem to indicate a diagnosis
of malignancy with virtually 100% specificity (for either PTCs or anaplastic thyroid carcinomas…

… (16) reported a correlation between BRAF V600E and small tumor size… BRAF positivity.
Another study by Hwang et al. (17) also demonstrated no significant associations between BRAF …